ArticleEuropean journal of cancer (Oxford, England : 1990)2022
Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment.
Article in European journal of cancer (Oxford, England : 1990), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Prognostic Effect of CEA Cut-Off in Patients with Resectable Colorectal Liver Metastases: A Meta-Analysis and Meta-Regression.Journal of gastrointestinal cancer · 2025Pooled it
- A critical appraisal of the current landscape of resectable BRAF mutated colorectal liver metastases: a systematic review.Chinese clinical oncology · 2024Pooled it
- Microwave coagulation for liver metastases.The Cochrane database of systematic reviews · 2024Pooled it
- Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis.Cells · 2023Pooled it
- CT-based radiomics improves survival prediction in colorectal liver metastases: beyond clinical scores.Updates in surgery · 2026Article
- Complete Resection of Simultaneous Hepatic and Pulmonary Metastases from Colorectal Cancer in the Era of Modern Systemic and Surgical Therapies: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2026Review
- Article
- CT radiomics for survival risk stratification in resectable colorectal liver metastases: a multi-centre study.Scientific reports · 2026Article
- The Clinical Relevance of Indeterminate Pulmonary Nodules in Patients Amenable to Local Treatment of Colorectal Liver Metastases.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2026Article
- Two Decades of Multimodal Management of Colorectal Liver Metastases With Long-Term Outcomes.ANZ journal of surgery · 2026Article
- The Molecular Signature of Early-Onset Colorectal Cancer Liver Metastases: Distinct Biology and Clinical Challenges.International journal of molecular sciences · 2026Review
- Predicting histopathological growth patterns and prognosis of colorectal liver metastases using MRI.European radiology · 2026Article
- Review
- AKR1B10 reprograms neutrophils by histone lactylation to foster immune evasion in KRASJournal of experimental & clinical cancer research : CR · 2026Article
- Hepatic Recurrence Rate Based on Extent of Adjuvant Floxuridine Exposure After Resection of Colorectal Liver Metastases.Annals of surgical oncology · 2026Article
- Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study.Journal of clinical medicine · 2026Article
- ASO Author Reflections: Radiomics for Predicting Survival Outcomes After Hepatic Resection of Colorectal Liver Metastases.Annals of surgical oncology · 2025Article
- CT-Based Radiomics Models with External Validation for Prediction of Recurrence and Disease-Specific Mortality After Radical Surgery of Colorectal Liver Metastases.Annals of surgical oncology · 2025Article
- Synergistic Anticancer Effects of Fibroblast Growth Factor Receptor Inhibitor and Cannabidiol in Colorectal Cancer.Nutrients · 2025Article
- Biomarkers of Survival in Patients with Colorectal Liver Metastases Treated with Percutaneous Microwave Ablation.Cancers · 2025Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundThe aim of this study was to develop a prediction model for 10-year overall survival (OS) after resection of colorectal liver metastasis (CRLM) based on patient, tumour and treatment characteristics.
methodsConsecutive patients after complete resection of CRLM were included from two centres (1992-2019). A prediction model providing 10-year OS probabilities was developed using Cox regression analysis, including KRAS, BRAF and histopathological growth patterns. Discrimination and calibration were assessed using cross-validation. A web-based calculator was built to predict individual 10-year OS probabilities.
resultsA total of 4112 patients were included. The estimated 10-year OS was 30% (95% CI 29-32). Fifteen patient, tumour and treatment characteristics were independent prognostic factors for 10-year OS; age, gender, location and nodal status of the primary tumour, disease-free interval, number and diameter of CRLM, preoperative CEA, resection margin, extrahepatic disease, KRAS and BRAF mutation status, histopathological growth patterns, perioperative systemic chemotherapy and hepatic arterial infusion pump chemotherapy. The discrimination at 10-years was 0.73 for both centres. A simplified risk score identified four risk groups with a 10-year OS of 57%, 38%, 24%, and 12%.
conclusionsTen-year OS after resection of CRLM is best predicted with a model including 15 patient, tumour, and treatment characteristics. The web-based calculator can be used to inform patients. This model serves as a benchmark to determine the prognostic value of novel biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.